Nasal Vaccines Market

Nasal Vaccines Market, By Vaccine type (Live attenuated vaccines, Inactivated vaccines, Subunit, recombinant, and conjugate vaccines, Others (such as DNA vaccines, viral vector vaccines, etc.)), By Application (Influenza, COVID-19, Other respiratory infections (such as RSV, pneumococcal, etc., Others (such as cholera, typhoid, etc.)), By End user (Pediatrics, Adults, Geriatrics, Others (such as travelers, military personnel, etc.), and By Geography (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Nasal vaccine is a vaccine administered through nose that stimulates an immune response without an injection. A vaccine dose is given via nose, rather than orally or through the arm. While several versions of a nasal vaccine are in development, most are in preclinical stages. The nasal vaccine is touted to have the ability to end the cycle of transmission, stop infection, and stop lung damage, including other adverse effects as the dose is administered through the nose, where the virus first enters our body. Thus, market players are focusing on developing safe/effective nasal vaccines.

Market Dynamics:

Rise in burden of respiratory diseases or infections, outbreak of COVID-19, increase in focus on the development of safe and effective vaccines, increasing demand for safe and effective vaccines, and increase in research and development activities are major factors expected to propel the growth of the global nasal vaccines market over the forecast period.

For instance, in January 2023, Bharat Biotech announced the launch of the India’s first intra-nasal COVID vaccine iNCOVACC for a primary as well as heterologous (mix-and-match) booster dose in India. It is the first nasal COVID-19 vaccine that has been approved both as a primary two-dose regimen, and a heterologous booster after two doses of Covishield or Covaxin. It is approved by the Drugs Control General of India (DCGI) as a heterologous booster dose. The new iNCOVACC vaccine can potentially revolutionize the battle against COVID-19 infection.

Key features of the study:

This report provides in-depth analysis of the global nasal vaccines market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year.

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.

It profiles key players in the global nasal vaccines market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.

Key companies covered as a part of this study include Intravacc, Vaxart, Inc., FluGen Inc., Altimmune, Inc., Sinovac Biotech Ltd., Sanofi Pasteur SA, Pfizer Inc., GlaxoSmithKline plc, AstraZeneca, Gamma Vaccines Pty Ltd., Ennaid Therapeutics, LLC, BiondVax Pharmaceuticals Ltd., Johnson & Johnson Services, Inc., Serum Institute of India Pvt. Ltd., and Bharat Biotech International Limited, among others.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.

The global nasal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nasal vaccines market.

Detailed Segmentation:

Global Nasal Vaccines Market, By Vaccine type:

Live Attenuated Vaccines

Inactivated Vaccines

Subunit, Recombinant, and Conjugate Vaccines

Others (such as DNA Vaccines, Viral Vector Vaccines, etc.)

Global Nasal Vaccines Market, By Application:

Influenza

COVID-19

Other Respiratory Infections (such as RSV, Pneumococcal, etc.)

Others (such as Cholera, Typhoid, etc.)

Global Nasal Vaccines Market, By End User:

Pediatrics

Adults

Geriatrics

Others (such as Travelers, Military Personnel, etc.)

Global Nasal Vaccines Market, By Region:

North America

Europe

Asia Pacific

Latin America

Middle East and Africa

Company Profiles:

Intravacc

Vaxart, Inc.

FluGen Inc.

Altimmune, Inc.

Sinovac Biotech Ltd.

Sanofi Pasteur SA

Pfizer Inc.

GlaxoSmithKline plc

AstraZeneca

Gamma Vaccines Pty Ltd.

Ennaid Therapeutics, LLC

BiondVax Pharmaceuticals Ltd.

Johnson & Johnson Services, Inc.

Serum Institute of India Pvt. Ltd.

Bharat Biotech International Limited